2 results
Approved WMORecruiting
The purpose of this Phase II/III study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of RO7204239, a humanized monoclonal antibody that binds to human latent myostatin, in combination with risdiplam (…
Approved WMORecruiting
•To compare progression-free survival (PFS) as assessed by blinded independent central review (BICR) between sacituzumab govitecan (SG) versus treatment of physician*s choice (TPC)Secondary Objectives:•To compare overall survival (OS) between the 2…